UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 87

Sortiert nach

Hepatitis C

The Lancet (British edition), 2015-03, Vol.385 (9973), p.1124-1135

2015

Link zum Volltext

Verfügbarkeit prüfen

Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3

The New England journal of medicine, 2014-05, Vol.370 (21), p.1993-2001

2014

Link zum Volltext

Verfügbarkeit prüfen

Treatment decisions and contemporary versus pending treatments for hepatitis C

Nature reviews. Gastroenterology & hepatology, 2013-12, Vol.10 (12), p.713

2013

Link zum Volltext

Verfügbarkeit prüfen

Hepatitis B virus infection

Nature reviews. Disease primers, 2018-06, Vol.4 (1), p.18035-18035, Article 18035

2018

Link zum Volltext

Verfügbarkeit prüfen

Temporal Analysis of Early Immune Responses in Patients With Acute Hepatitis B Virus Infection

Gastroenterology (New York, N.Y. 1943), 2009-10, Vol.137 (4), p.1289-1300

2009

Link zum Volltext

Verfügbarkeit prüfen

Evidence of a Large, International Network of HCV Transmission in HIV-Positive Men Who Have Sex With Men

Gastroenterology (New York, N.Y. 1943), 2009-05, Vol.136 (5), p.1609-1617

2009

Link zum Volltext

Verfügbarkeit prüfen

Kinetics of hepatitis B surface antigen loss in patients with HBeAg-positive chronic hepatitis B treated with tenofovir disoproxil fumarate

Journal of hepatology, 2014-12, Vol.61 (6), p.1228-1237

2014

Link zum Volltext

Verfügbarkeit prüfen

Eltrombopag Increases Platelet Numbers in Thrombocytopenic Patients With HCV Infection and Cirrhosis, Allowing for Effective Antiviral Therapy

Gastroenterology (New York, N.Y. 1943), 2014-02, Vol.146 (2), p.442-452.e1

2014

Link zum Volltext

Verfügbarkeit prüfen

Chronic Hepatitis B Virus Infection: Disease Revisit and Management Recommendations

Journal of clinical gastroenterology, 2016-04, Vol.50 (4), p.286-294

2016

Link zum Volltext

Verfügbarkeit prüfen

High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials

Hepatology (Baltimore, Md.), 2012-12, Vol.56 (6), p.2039-2050

2012

Link zum Volltext

Verfügbarkeit prüfen

Peginterferon Alfa-2a in Patients with Chronic Hepatitis C and Cirrhosis

The New England journal of medicine, 2000-12, Vol.343 (23), p.1673-1680

2000

Link zum Volltext

Verfügbarkeit prüfen

Ribavirin and interferon alfa‐2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions

British journal of clinical pharmacology, 1998-12, Vol.46 (6), p.563-570

1998

Link zum Volltext

Verfügbarkeit prüfen

TMC435 for the treatment of chronic hepatitis C

Expert opinion on investigational drugs, 2012-08, Vol.21 (8), p.1193-1209

2012

Link zum Volltext

Verfügbarkeit prüfen

Cost-effectiveness of oral treatments for chronic hepatitis B

Journal of hepatology, 2009-10, Vol.51 (4), p.623-625

Dusheiko, Geoffrey M

2009

Link zum Volltext

Verfügbarkeit prüfen

Applying a system approach to forecast the total hepatitis C virus-infected population size: model validation using US data

Liver international, 2011-07, Vol.31 (s2), p.4-17

2011

Link zum Volltext

Verfügbarkeit prüfen

Non-cirrhotic thrombocytopenic patients with hepatitis C virus: Characteristics and outcome of antiviral therapy

Journal of gastroenterology and hepatology, 2015-08, Vol.30 (8), p.1301-1308

2015

Link zum Volltext

Verfügbarkeit prüfen

Monitoring the Emergence of Hepatitis B Virus Polymerase Gene Variants during Lamivudine Therapy Using the LightCycler

Journal of Clinical Microbiology, 2001-04, Vol.39 (4), p.1456-1459

2001

Link zum Volltext

Verfügbarkeit prüfen

Kinetics of acute hepatitis B virus infection in humans

The Journal of experimental medicine, 2001-04, Vol.193 (7), p.847-854

2001

Link zum Volltext

Verfügbarkeit prüfen

Sustained Virologic Response Rates With Telaprevir-Based Therapy in Treatment-Naive Patients Evaluated by Race or Ethnicity

Journal of clinical gastroenterology, 2015-04, Vol.49 (4), p.336-344

2015

Link zum Volltext

Verfügbarkeit prüfen

Safety of peginterferon alfa-2a plus ribavirin in a large multinational cohort of chronic hepatitis C patients

Liver international, 2012-09, Vol.32 (8), p.1270-1277

2012

Link zum Volltext

Verfügbarkeit prüfen

Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin: Analyses of Pre-Defined Subpopulations in the Phase 3 Advance Trial

Gastroenterology (New York, N.Y. 1943), 2011, Vol.140 (5), p.S-908-S-908

2011

Link zum Volltext

Verfügbarkeit prüfen

Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin Increased Sustained Virologic Response Rates in Treatment-NaïVE Patients Regardless of Race or Ethnicity

Gastroenterology (New York, N.Y. 1943), 2011, Vol.140 (5), p.S-908-S-908

2011

Link zum Volltext

Verfügbarkeit prüfen

Hepatitis C and treatment with pegylated interferon and ribavirin

The international journal of biochemistry & cell biology, 2004-10, Vol.36 (10), p.1874-1877

2004

Link zum Volltext

Verfügbarkeit prüfen

M1782 Characteristics of HBeAg-Positive Patients with HBsAg Loss/Seroconversion Following Treatment with Tenofovir Disoproxil Fumarate (TDF)

Gastroenterology (New York, N.Y. 1943), 2009, Vol.136 (5), p.A-837-A-837

2009

Link zum Volltext

Verfügbarkeit prüfen

311 Final Results of a Rollover Study Assessing Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Chronic HCV Patients With Well-Characterized Null Response, Partial Response, Viral Breakthrough, or Relapse After Prior PR Treatment

Gastroenterology (New York, N.Y. 1943), 2010, Vol.138 (5), p.S-782-S-783

2010

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 87

Suche als RSS-Feed

Aktive Filter

ThemaInfectious Diseases

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(80)
Mit Volltextzugriff
(78)

Publikationsform

Artikel
(84)
Buchkapitel
(3)

Sprache

Englisch
(87)
Japanisch
(9)

Erscheinungsjahr

n.n

Thema

Humans
(62)
Science & Technology
(53)
Life Sciences & Biomedicine
(51)
Adult
(35)
Gastroenterology & Hepatology
(33)
Female
(32)
Male
(31)
Middle Aged
(31)
Antiviral Agents - Therapeutic Use
(23)
Biological And Medical Sciences
(21)
Medical Sciences
(20)
Aged
(19)
Adolescent
(16)
Gastroenterology And Hepatology
(15)
Hepatitis C
(14)
Hepatitis C, Chronic - Drug Therapy
(13)
Pharmacology. Drug Treatments
(12)
Interferon-Alpha - Therapeutic Use
(11)
Antiviral Agents
(10)
Ribavirin - Therapeutic Use
(10)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Hepatitis C

Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3

Treatment decisions and contemporary versus pending treatments for hepatitis C

Hepatitis B virus infection

Temporal Analysis of Early Immune Responses in Patients With Acute Hepatitis B Virus Infection

Evidence of a Large, International Network of HCV Transmission in HIV-Positive Men Who Have Sex With Men

Kinetics of hepatitis B surface antigen loss in patients with HBeAg-positive chronic hepatitis B treated with tenofovir disoproxil fumarate

Eltrombopag Increases Platelet Numbers in Thrombocytopenic Patients With HCV Infection and Cirrhosis, Allowing for Effective Antiviral Therapy

Chronic Hepatitis B Virus Infection: Disease Revisit and Management Recommendations

High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials

Peginterferon Alfa-2a in Patients with Chronic Hepatitis C and Cirrhosis

Ribavirin and interferon alfa‐2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions

TMC435 for the treatment of chronic hepatitis C

Cost-effectiveness of oral treatments for chronic hepatitis B

Applying a system approach to forecast the total hepatitis C virus-infected population size: model validation using US data

Non-cirrhotic thrombocytopenic patients with hepatitis C virus: Characteristics and outcome of antiviral therapy

Monitoring the Emergence of Hepatitis B Virus Polymerase Gene Variants during Lamivudine Therapy Using the LightCycler

Kinetics of acute hepatitis B virus infection in humans

Sustained Virologic Response Rates With Telaprevir-Based Therapy in Treatment-Naive Patients Evaluated by Race or Ethnicity

Safety of peginterferon alfa-2a plus ribavirin in a large multinational cohort of chronic hepatitis C patients

Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin: Analyses of Pre-Defined Subpopulations in the Phase 3 Advance Trial

Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin Increased Sustained Virologic Response Rates in Treatment-NaïVE Patients Regardless of Race or Ethnicity

Hepatitis C and treatment with pegylated interferon and ribavirin

M1782 Characteristics of HBeAg-Positive Patients with HBsAg Loss/Seroconversion Following Treatment with Tenofovir Disoproxil Fumarate (TDF)

311 Final Results of a Rollover Study Assessing Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Chronic HCV Patients With Well-Characterized Null Response, Partial Response, Viral Breakthrough, or Relapse After Prior PR Treatment

Aktive Filter

Suchergebnisse filtern